CATT at 5 years: Visual acuity gains not maintained

SAN FRANCISCO — Regardless of treatment drug, either bevacizumab or ranibizumab, visual acuity gains seen in the first 2 years of the CATT study were not maintained at year 5, study chair Daniel F. Martin, MD, reported here.Speaking at the American Society of Retina Specialists annual meeting, Martin said, “Between year 2 and year 5, there was a mean 11-letter decrease, such that at 5 years, the average patient was three letters worse than they were at baseline.”